Irwin Hollander

3.0k total citations
46 papers, 2.4k citations indexed

About

Irwin Hollander is a scholar working on Molecular Biology, Organic Chemistry and Cancer Research. According to data from OpenAlex, Irwin Hollander has authored 46 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 20 papers in Organic Chemistry and 8 papers in Cancer Research. Recurrent topics in Irwin Hollander's work include PI3K/AKT/mTOR signaling in cancer (26 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Irwin Hollander is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (26 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Irwin Hollander collaborates with scholars based in United States, Canada and Netherlands. Irwin Hollander's co-authors include Robert Mallon, Ker Yu, Semiramis Ayral‐Kaloustian, Larry Feldberg, Judy Lucas, Philip R. Hamann, Natasja Brooijmans, Lourdes Toral‐Barza, Aranapakam M. Venkatesan and Arie Zask and has published in prestigious journals such as Nature Biotechnology, Analytical Chemistry and Neurology.

In The Last Decade

Irwin Hollander

45 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Irwin Hollander United States	29	1.3k	851	501	342	284	46	2.4k
Carolyn Discafani United States	23	1.4k 1.0×	872 1.0×	1.4k 2.8×	357 1.0×	205 0.7×	30	3.0k
Timothy B. Lowinger United States	20	1.3k 1.0×	742 0.9×	843 1.7×	228 0.7×	305 1.1×	53	2.7k
John S. McMurray United States	31	1.6k 1.2×	551 0.6×	1.1k 2.2×	255 0.7×	199 0.7×	79	2.8k
Giorgio Caravatti Switzerland	26	1.5k 1.1×	660 0.8×	713 1.4×	149 0.4×	105 0.4×	45	2.3k
Jeff B. Smaill New Zealand	30	1.9k 1.4×	1.0k 1.2×	1.0k 2.1×	235 0.7×	118 0.4×	95	3.4k
Robert S. Kania United States	16	1.6k 1.2×	908 1.1×	474 0.9×	195 0.6×	125 0.4×	23	2.4k
Karen Lackey United States	21	1.3k 1.0×	883 1.0×	1.3k 2.6×	448 1.3×	102 0.4×	32	2.8k
M. V. Ramana Reddy United States	23	933 0.7×	733 0.9×	488 1.0×	115 0.3×	111 0.4×	80	2.1k
Scott H. Dickerson United States	19	1.2k 0.9×	778 0.9×	880 1.8×	266 0.8×	120 0.4×	29	2.2k
Joseph Schoepfer Switzerland	24	1.5k 1.1×	532 0.6×	470 0.9×	137 0.4×	97 0.3×	43	2.0k

Countries citing papers authored by Irwin Hollander

Since Specialization

Citations

This map shows the geographic impact of Irwin Hollander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irwin Hollander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irwin Hollander more than expected).

Fields of papers citing papers by Irwin Hollander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irwin Hollander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irwin Hollander. The network helps show where Irwin Hollander may publish in the future.

Co-authorship network of co-authors of Irwin Hollander

This figure shows the co-authorship network connecting the top 25 collaborators of Irwin Hollander. A scholar is included among the top collaborators of Irwin Hollander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irwin Hollander. Irwin Hollander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mallon, Robert, Larry Feldberg, Judy Lucas, et al.. (2011). Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor. Clinical Cancer Research. 17(10). 3193–3203. 145 indexed citations

Dehnhardt, Christoph M., Aranapakam M. Venkatesan, Zecheng Chen, et al.. (2011). Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(16). 4773–4778. 30 indexed citations

Mallon, Robert, Irwin Hollander, Larry Feldberg, et al.. (2010). Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor. Molecular Cancer Therapeutics. 9(4). 976–984. 52 indexed citations

Tsou, Hwei‐Ru, Gary H. Birnberg, Nan Zhang, et al.. (2010). 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorganic & Medicinal Chemistry Letters. 20(7). 2259–2263. 19 indexed citations

Curran, Kevin J., Jeroen C. Verheijen, Joshua A. Kaplan, et al.. (2010). Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent. Bioorganic & Medicinal Chemistry Letters. 20(4). 1440–1444. 61 indexed citations

Bursavich, Matthew G., Natasja Brooijmans, Irwin Hollander, et al.. (2010). Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of rapamycin: Hit to lead studies. Bioorganic & Medicinal Chemistry Letters. 20(8). 2586–2590. 26 indexed citations

Venkatesan, Aranapakam M., Zecheng Chen, Osvaldo dos Santos, et al.. (2010). PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorganic & Medicinal Chemistry Letters. 20(19). 5869–5873. 59 indexed citations

Zask, Arie, Jeroen C. Verheijen, David J. Richard, et al.. (2010). Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(8). 2644–2647. 33 indexed citations

Verheijen, Jeroen C., Ker Yu, Lourdes Toral‐Barza, Irwin Hollander, & Arie Zask. (2009). Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K. Bioorganic & Medicinal Chemistry Letters. 20(1). 375–379. 32 indexed citations

10.

Richard, David J., Jeroen C. Verheijen, Kevin J. Curran, et al.. (2009). Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability. Bioorganic & Medicinal Chemistry Letters. 19(24). 6830–6835. 42 indexed citations

11.

Gilbert, A., Paweł Nowak, Natasja Brooijmans, et al.. (2009). Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-α: Hit to lead studies. Bioorganic & Medicinal Chemistry Letters. 20(2). 636–639. 32 indexed citations

12.

Venkatesan, Aranapakam M., Christoph M. Dehnhardt, Zecheng Chen, et al.. (2009). Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(2). 653–656. 23 indexed citations

13.

Kaplan, Joshua A., Jeroen C. Verheijen, Natasja Brooijmans, et al.. (2009). Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorganic & Medicinal Chemistry Letters. 20(2). 640–643. 41 indexed citations

14.

Hollander, Irwin, Frédéric Marion, David E. Williams, et al.. (2006). Liphagal, a new meroterpenoid from the Caribbean sponge Aka coralliphaga that shows potent and selective inhibition of P13 kinase alpha.. Clinical Cancer Research. 11(24).

15.

Hollander, Irwin, et al.. (2003). Human Ras converting enzyme endoproteolytic specificity at the P2′ and P3′ positions of K-Ras-derived peptides. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1649(1). 24–29. 7 indexed citations

16.

Mallon, Robert, Larry Feldberg, Steven C. Kim, et al.. (2001). An Enzyme-Linked Immunosorbent Assay for the Raf/MEK1/MAPK Signaling Cascade. Analytical Biochemistry. 294(1). 48–54. 23 indexed citations

17.

Hollander, Irwin, et al.. (2000). Human Ras-Converting Enzyme (hRCE1) Endoproteolytic Activity on K-Ras-Derived Peptides. Analytical Biochemistry. 286(1). 129–137. 29 indexed citations

18.

Discafani, Carolyn, Marion L. Carroll, M. Brawner Floyd, et al.. (1999). Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochemical Pharmacology. 57(8). 917–925. 84 indexed citations

19.

Loose, Jeffrey H., et al.. (1992). Adenomyoepithelioma of the Breast. The American Journal of Surgical Pathology. 16(9). 868–876. 123 indexed citations

20.

Siegel, Marshall M., Irwin Hollander, Philip R. Hamann, et al.. (1991). Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content. Analytical Chemistry. 63(21). 2470–2481. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact